SynthesisFrontiers in psychiatry2026
A novel application of stellate ganglion block to improve sleep: a systematic review and meta-analysis.
Synthesis in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sleep is essential for optimal health; however, the prevalence of poor sleep, characterized by disrupted patterns and qualities, adversely affects psychological well-being and cognitive function. This issue is prevalent, yet it is frequently underdiagnosed and inadequately managed. Current therapeutic options exhibit notable limitations. The Stellate Ganglion Block (SGB) may alleviate sleep disturbances through various physiological mechanisms; however, its safety and efficacy remain subjects of ongoing debate. This meta-analysis systematically evaluates the efficacy of SGB using objective metrics to provide high-quality clinical evidence and to inform future research directions. Methods: Literature searches were conducted in PubMed, Web of Science, Embase, the Cochrane Library, OVID, and Google Scholar from database inception to June 2025. Analyses were performed with RevMan 5.4 software, and the study was registered on PROSPERO (CRD420251040732) . Results: Seven studies met the inclusion criteria. In comparison to the control group, patients who received the SGB demonstrated a statistically significant increase in total sleep time (WMD: 60.86; 95% CI, 38.05 to 83.66; P < 0.001). Additionally, these patients exhibited lower scores on the Pittsburgh Sleep Quality Index (PSQI) (WMD: -1.22; 95% CI, -1.80 to -0.65; P < 0.001), reduced sleep onset latency (WMD: -1.59; 95% CI, -2.48 to -0.69; P < 0.001), and enhanced deep sleep quality, as indicated by lower scores on the deep sleep quality assessment (WMD: -1.42; 95% CI, -1.95 to -0.89; P < 0.001). Conclusion: The SGB shows promise in alleviating sleep problems. However, a lack of high-quality studies, insufficient long-term follow-up, and incomplete participant demographic data limit the existing evidence. There is a pressing need for extended follow-up and multicenter randomized controlled trials (RCTs). Future research should explore the potential synergies between stellate ganglion block and cognitive behavioral therapy (CBT-I) for sleep disorder to assess the sustainability of its efficacy and to expand the population that may benefit from this intervention. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/, identifier CRD420251040732.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.